BridgeBio Oncology Therapeutics (BBOT) Q3 2025 earnings summary

Executive summary

• Advanced three lead oncology programs: BBO-8520 (KRAS G12C inhibitor, Fast Track designated), BBO-10203 (RAS-PI3Kα breaker), and BBO-11818 (pan-KRAS inhibitor), all in Phase 1 trials with initial data expected in 2026.

• Debuted as a publicly traded company focused on RAS and PI3Kα-driven tumor therapies, following a de-SPAC transaction with Helix Acquisition Corp. II in August 2025, raising $373.5M in gross proceeds including PIPE financing.

• Transitioned from a subsidiary of BridgeBio Pharma to an independent public company, with significant related party transactions and operational carve-out through April 2024.

• Appointed Uneek Mehra as Chief Financial Officer, bringing 28+ years of industry experience.

Financial highlights

• Net loss of $44.8M for Q3 2025, up from $17.3M in Q3 2024; net loss of $95.2M for the nine months ended September 30, 2025.

• Operating expenses rose 150% year-over-year in Q3 2025, driven by a 96% increase in R&D and a 696% increase in G&A expenses.

• Cash, cash equivalents, and marketable securities totaled $468.3M as of September 30, 2025, providing runway into 2028.

• Interest income increased to $3.4M in Q3 2025, reflecting higher cash balances post-transaction.

• Weighted-average shares outstanding increased to 43.5 million in Q3 2025 from 11,089 in Q3 2024.

Outlook and guidance

• Current cash position expected to fund operations into 2028, but not through full regulatory approval for all candidates; additional capital will be needed for late-stage development and commercialization.

• Anticipates continued significant operating losses as clinical programs advance and public company costs increase.

• Initial clinical data from lead programs expected throughout 2026.